Suven Life Sciences on 30 December 2014 announced that it has been granted product patents for its drugs used in the treatment of neurodegenerative diseases like Alzheimer's disease, Schizophrenia and Parkinson's disease.
One each product patent has been granted by Eurasia, Japan and Mexico each and is valid until 2029. With this, Suven has total granted patents of 13 from Eurasia, 12 from Japan and 17 from Mexico.
The product patents correspond to the new chemical entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases.
The patents are exclusive intellectual property of Suven products which may be out-licensed at various phases of clinical development like at Phase-1 and Phase-2.
Suven Life Sciences was incorporated in 1989, by Venkat Jasti. It is pioneering efforts in C-R-A-M-S relationships with 22 Global Life Science majors IPO in 1995. It was listed on NSE and BSE in India.
When: 30 December 2014
DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.